Johnson & Johnson 10-Q Summary: Fiscal Third Quarter Ended September 28, 2008
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Johnson & Johnson, a large accelerated filer incorporated in New Jersey. The report covers the fiscal third quarter ended September 28, 2008, and the fiscal nine months ended on that date. The company operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Sales (Revenue) | $15.92 Billion | $14.97 Billion | $48.57 Billion | $45.14 Billion |
| Net Earnings | $3.31 Billion | $2.55 Billion | $10.24 Billion | $8.20 Billion |
| Diluted EPS | $1.17 | $0.88 | $3.60 | $2.81 |
| Gross Margin | 70.0% | 71.5% | 70.9% | 71.2% |
| Operating Profit | $4.29 Billion | $3.27 Billion | $13.41 Billion | $10.95 Billion |
| Cash Flow from Operations | N/A | N/A | $10.97 Billion | $10.93 Billion |
| Cash & Equivalents (End of Period) | $14.02 Billion | $6.64 Billion | $14.02 Billion | $6.64 Billion |
| Total Debt (Short + Long Term) | $14.64 Billion | $9.54 Billion | $14.64 Billion | $9.54 Billion |
Note: Debt figures calculated as sum of "Loans and notes payable" and "Long-term debt" from the Balance Sheet.
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 6.4% in Q3 and 7.6% for the nine-month period. Growth was driven by a 13.1% increase in international sales, while U.S. sales remained relatively flat (0.4% increase in Q3). Currency fluctuations provided a positive impact of 3.1% in Q3 and 4.6% for the nine months.
- Profitability: Net earnings rose 30% in Q3 and 25% for the nine months compared to the prior year. This improvement was significantly aided by the absence of the $745 million restructuring charge and $807 million in-process research and development (IPR&D) charge recorded in the same periods of 2007.
- Segment Performance:
- Consumer: Sales grew 13.1% in Q3, driven by strong performance in Skin Care and OTC Pharmaceuticals.
- Pharmaceutical: Sales were flat (0.2% growth) in Q3 due to a 6.0% decline in U.S. sales, largely attributed to the loss of market exclusivity for Risperdal oral and generic competition for other key products (Levaquin, Duragesic). International sales grew 10.3%.
- Medical Devices: Sales grew 8.8% in Q3, with international sales up 14.3%. Growth was offset by a 10.2% operational decline in the Cordis franchise due to competition in the drug-eluting stent market.
- Balance Sheet: Cash and cash equivalents increased significantly to $14.02 billion from $7.77 billion at year-end 2007. Total debt increased to $14.64 billion, primarily to fund a common stock repurchase program.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted strong operational growth in Consumer and Medical Devices segments. The Pharmaceutical segment faced headwinds from patent expirations and generic competition, particularly for Risperdal, Levaquin, and Duragesic. However, new product launches (e.g., Zyrtec OTC, Concerta) and growth in biologics (Remicade) provided offsets.
- Legal Proceedings: The company faces significant litigation risks, including:
- Product Liability: Claims related to Ortho Evra, Risperdal, Duragesic, and the Charité Artificial Disc.
- Patent Litigation: Ongoing disputes regarding drug-eluting stents (Cordis vs. Boston Scientific/Medtronic) and generic challenges to key drugs like Risperdal, Concerta, and Levaquin.
- Government Investigations: Subpoenas and inquiries regarding marketing practices (Risperdal, Topamax, Natrecor), the Iraq Oil for Food program, and potential Foreign Corrupt Practices Act (FCPA) violations.
- Unusual Items:
- Restructuring: No restructuring charges were recorded in Q3 2008, compared to $745 million in Q3 2007.
- IPR&D: A $40 million charge was recorded in the first nine months of 2008 (vs. $807 million in 2007) related to the acquisition of Amic AB.
- Settlements: A $200 million settlement payment was received from Amgen in Q3 2008, recorded as a gain in "Other (income) expense, net."
- Capital Allocation: The company repurchased $5.77 billion of common stock in the first nine months of 2008. Dividends per share increased to $0.460 in Q3 2008 from $0.415 in Q3 2007.
Investor Verification Checklist
- Patent Expirations: Verify the timeline and impact of generic entry for Risperdal, Levaquin, and Concerta on future revenue projections.
- Legal Exposure: Review the status of the Risperdal state attorney general actions and the outcome of the stent patent litigation against Boston Scientific and Medtronic.
- Debt Levels: Assess the sustainability of the increased debt load ($14.6B) taken on to fund stock buybacks in a rising interest rate environment.
- Pharmaceutical Mix: Analyze the dependency on Remicade and the pipeline for new launches to offset the decline in legacy small-molecule drugs.
- Regulatory Compliance: Monitor the resolution of ongoing government investigations regarding marketing practices and the FCPA disclosures.